antifungal agent :
Search Words
News & Articles
- Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161
Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis and is being conducted at leading clinical centers in the United States.
Sept. 5, 2013 - Business Wire via Yahoo! Finance